Other Clinical Trial - A Phase I Intravesical PPM Therapy for NMIBC

Status Recruiting

Clinical Trial Summary

This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micelle (PPM)." PPM is tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer that does not invade into the muscle layer of the bladder and that has failed the treatment of another drug BCG. Up to 29 patients will be enrolled into the trial. The main goal of this trial is to determine the dose of PPM for future clinical trials, assess the toxicity and obtain preliminary data regarding its effectiveness.

Clinical Trial Description

The goal of this project is to conduct a Phase I clinical trial to determine the recommended Phase II dose (RP2D) of bladder cancer-targeting micelles loaded with a chemotherapeutic drug paclitaxel (PTX). The investigators previously developed a bladder cancer-specific targeting ligand named PLZ4, and a PLZ4-coated PTX-loaded nanoscale micelle (PPM) platform that can specifically deliver the drug load into bladder cancer cells both in vitro and in vivo. This proposed clinical trial is to conduct a first-in-human trial to use PPM for the treatment of non-myoinvasive bladder cancer (NMIBC). This primary objective of the proposed Phase I trial is to determine the recommended Phase II dose (RP2D) of PPM. The secondary objectives are to assess the toxicity, obtain preliminary efficacy information of PPM, and determine systemic absorption after intravesical instillation of PPM. Up to 29 patients with recurrent or refractory NMIBC after a standard first-line intravesical BCG treatment will be recruited. PPM will be given as intravesical instillation once weekly for six weeks. The toxicity will be assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The efficacy will be determined by urine cytology and cystoscopy after finishing treatment. Molecular correlative studies will be performed. ;

Study Design

Related Conditions & MeSH terms

Non-muscle-invasive Bladder Cancer
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT05519241
Study type	Interventional
Source	VA Office of Research and Development
Contact	Chong-Xian Pan, MD PhD
Phone	(857) 203-6189
Email	chong-xian.pan@va.gov
Status	Recruiting
Phase	Phase 1
Start date	October 10, 2022
Completion date	August 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05483868` - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer	Phase 1
Not yet recruiting	`NCT05547516` - Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients	N/A
Not yet recruiting	`NCT05580354` - Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer	Phase 4
Not yet recruiting	`NCT05002556` - AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Recruiting	`NCT05544552` - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Phase 1/Phase 2
Recruiting	`NCT05796375` - Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance	N/A
Active, not recruiting	`NCT03528694` - Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer	Phase 3
Recruiting	`NCT05790850` - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)	N/A
Completed	`NCT03664258` - A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Not yet recruiting	`NCT05962541` - Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)	Phase 4
Active, not recruiting	`NCT05864599` - External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
Not yet recruiting	`NCT03950362` - Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer	Phase 2
Recruiting	`NCT05710848` - A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT05232136` - OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT05825950` - Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting	`NCT05626101` - Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study	N/A
Recruiting	`NCT05538663` - Intravesical BCG vs GEMDOCE in NMIBC	Phase 3
Recruiting	`NCT06245759` - The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
Active, not recruiting	`NCT04690699` - LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT05675176` - Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer